High-Dose Quadrivalent Vaccine Remains Preferentially Recommended to Protect Seniors in Canada

As flu shots arrive in local pharmacies next month, Canadians will have different vaccines to choose which is best for their needs.

To assist this decision process, the Canadian National Advisory Committee on Immunization’s (NACI) annual Statement on Seasonal Influenza Vaccines for 2024-2025 recommends Fluzone® High-Dose Quadrivalent among the preferential influenza vaccines over standard-dose influenza vaccines.

According to NACI on July 26, 2024, Fluzone® High-Dose Quadrivalent has the most substantial body of supporting evidence among preferentially recommended vaccines for adults 65 years of age and older.

Dr. Angel Chu MD, FRCPC, Infectious disease specialist, Clinical Assistant Professor, University of Calgary, STI Clinic Calgary, and Vice-Chair of Immunize Canada, commented in a press release, “In the newest NACI statement, Fluzone® High-Dose continues to be recommended for adults 65 years of age and older. NACI also recognizes Fluzone® High-Dose has the most substantial body of supporting evidence among flu vaccines for seniors.”

Influenza can cause mild to severe illness. Some populations, especially young children and adults 65 and older, are at a higher risk for serious influenza complications.

Sanofi says vaccination is the most effective way to prevent influenza and its complications.

Earlier this year, the WHO recommended that trivalent vaccines be deployed during the 2024-2025 northern hemisphere influenza season.

On June 27, 2024, the U.S. Centers for Disease Control and Prevention vaccine committee meeting included presentations focused on Considerations and Proposed Recommendations for the 2024-25 Influenza Season in the United States. Physicians, nurses, and pharmacists can offer patients up to nine different influenza vaccines for the 2024 - 2025 flu season.